openPR Logo
Press release

Proteros and University of Cincinnati, Drug Discovery Center establish collaboration to offer high-throughput screening services and access to a 340,000+ compound library

03-09-2011 12:07 PM CET | Science & Education

Press release from: Proteros biostructures GmbH

/ PR Agency: BCNP Consultants GmbH
Martinsried, Germany, March 09, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into an agreement with University of Cincinnati, Drug Discovery Center (UC DDC), under which Proteros will provide biotech and pharmaceutical companies with access to UC DDC’s ultra-high-throughput and high-content screening platform coupled with a 340,000-plus library of drug-like compounds. Proteros will be responsible for all the client interactions and project management providing a single point of contact.

Proteros now offers a comprehensive range of services for drug discovery from its own integrated lead discovery platform that includes a 30,000 member proprietary compound and fragment library, innovative kinetic and thermodynamic HTS assay technologies and structure guided medicinal chemistry to a traditional high-throughput screening approach. The structure guided approach is particularly suited to kinase targets, epigenetics targets and protein- protein interactions.

Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be able to offer this broad collection of discovery services to meet the diverse target and project needs of our clients. Proteros continues to enhance its service offering to enable our clients to improve the quality and productivity of their discovery efforts.”

“This powerful academic-industry collaboration in translational research combines leading capabilities at the UC DDC with Proteros’ proven technical and commercial expertise in providing discovery services and will continue to expand our base of pharmaceutical and biotechnology clients” said Dr. Ruben Papoian, Director, UC DDC.

About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

About UC DDC:
The Drug Discovery Center at the University of Cincinnati is dedicated to the discovery and early development of novel and commercially viable therapeutic entities. The Drug Discovery Center is designed to fulfill both scientific and commercial objectives. Since becoming fully operational in mid-2006, the center has served academic, nonprofit and for-profit biomedical research organizations throughout the United States and Europe. To date, the Drug Discovery Center has run over 50 individual projects from 25 different academic, industrial and federal partners using more than1 million compounds.

Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

Drug Discovery Center
University of Cincinnati
Ruben Papoian, Ph.D.
Director, Drug Discovery Center
University of Cincinnati
2180 E. Galbraith Road, D243
Cincinnati, Ohio 45237
Phone: +1 513 558 0516
Email: ruben.papoian@uc.edu
Internet: www.drugdiscovery.uc.edu

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros and University of Cincinnati, Drug Discovery Center establish collaboration to offer high-throughput screening services and access to a 340,000+ compound library here

News-ID: 165743 • Views: 1135

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning